RecruitingNot ApplicableNCT07513311

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

Pilot Feasibility Trial of a Nurse-Led, Coping and Supportive Intervention (RESTORE) for Patients With Triple-Negative Breast Cancer

Sponsor

Massachusetts General Hospital

Enrollment

75 participants

Start Date

Jul 7, 2026

Study Type

INTERVENTIONAL

Conditions

Triple Negative Breast Cancer(TNBC)

Summary

The purpose of this study is to explore the feasibility and acceptability of a nurse-led, coping, and supportive care intervention for patients with triple-negative breast cancer. The intervention aims to improve psychosocial outcomes in patients with triple-negative breast cancer (e.g., quality of life (QOL), anxiety, fear of cancer recurrence (FCR)).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a behavioral approach called Enhanced Usual Care and a behavioral approach called RESTORE for people with triple negative breast cancer(tnbc). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALRESTORE

RESTORE is a nurse-led, small group-based, virtual (teleconference) cognitive-behavioral therapy-based intervention. The intervention incorporates psychoeducation, problem-solving, cognitive restructuring, relaxation training, symptom management skills training, coping effectiveness training, and mindfulness techniques.

BEHAVIORALEnhanced Usual Care

Participants will receive educational information on breast cancer survivorship care in addition to usual care.

Locations(1)

Massachusetts General Hospital

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07513311

Related Trials

Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

NCT076522422 locations

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

NCT0702011712 locations

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer

NCT066493311 location

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NCT0498111916 locations

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

NCT07545122